Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study - ScienceDirect
Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants | ImmunoHorizons
High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma | Science Advances
Systemic administration of low-dose resiquimod induces activation of... | Download Scientific Diagram
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer | Nature Communications
Resiquimod - an overview | ScienceDirect Topics
Resiquimod | C17H22N4O2 - PubChem
Pharmaceutics | Free Full-Text | A Squalene-Based Nanoemulsion for Therapeutic Delivery of Resiquimod | HTML
Topical Resiquimod Protects against Visceral Infection with Leishmania infantum chagasi in Mice | Clinical and Vaccine Immunology
Resiquimod (R848) | TLR7/8 Agonist | MedChemExpress
Resiquimod - an overview | ScienceDirect Topics
Effects of treatments with resiquimod and/or PD-L1 blockade in Colon 26... | Download Scientific Diagram
Resiquimod (R848) | TLR7/8 Agonist | MedChemExpress
Recent clinical trends in Toll‐like receptor targeting therapeutics - Anwar - 2019 - Medicinal Research Reviews - Wiley Online Library
Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy. - Abstract - Europe PMC
Resiquimod - Wikipedia
Frontiers | Cancer Vaccines, Adjuvants, and Delivery Systems
The relative potency of BBIQ, resiquimod and imiquimod for human TLR7... | Download Scientific Diagram
Topical Resiquimod Protects against Visceral Infection with Leishmania infantum chagasi in Mice | Clinical and Vaccine Immunology
Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01 - ScienceDirect
Frontiers | Anti-tumor Activity of Toll-Like Receptor 7 Agonists
Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy | Oncotarget
Resiquimod PM induces T H 1 polarization of immune cells in the TME.... | Download Scientific Diagram
Ascendis files IND for sustained-release, anti-cancer TLR drug | Fierce Pharma
Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants | ImmunoHorizons
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies | Journal for ImmunoTherapy of Cancer | Full Text
Resiquimod is an effective therapy for early-stage CTCL. Changes from... | Download Scientific Diagram
Pharmaceutics | Free Full-Text | TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases | HTML
